CA125-related Measures of Tumor Kinetics and Outcome of Patients with Recurrent Ovarian Cancer Receiving Chemotherapy: A Retrospective Evaluation

被引：5
|
作者：
Colloca, Giuseppe [1 ]
Venturino, Antonella [1 ]
Addamo, Gianfranco [1 ]
Coccorullo, Zaira [1 ]
Ratti, Riccardo [1 ]
Caltabiano, Graziano [1 ]
Guarneri, Domenico [1 ]
机构：
[1] G Borea Hosp, Div Med Oncol, San Remo, Italy
来源：
JAPANESE JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 43卷 / 12期
关键词：
Ovarian cancer; tumor growth rate; chemotherapy; surrogate end point; PEGYLATED LIPOSOMAL DOXORUBICIN; RESPONSE CRITERIA; CA125; RESPONSE; DOUBLING TIME; GROWTH-RATE; THERAPY;
D O I：
10.1093/jjco/hyt139
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Defining the reliability of cancer antigen-125-related kinetics criteria versus Gynecologic Cancer Inter Group criteria in predicting the tumor outcome after chemotherapy in patients with recurrent ovarian cancer. A retrospective monoinstitutional assessment of CA125-related versus Gynecologic Cancer Inter Group-related parameters was performed after cytotoxic chemotherapy in patients with metastatic ovarian cancer treated from 2006 to 2011. A correlation analysis between the response and progression measurements has been performed, and the outcome has been reported. Among 42 eligible patients, tumor response and progression calculated by CA125 kinetics, with tumor response at 8 weeks and specific growth rate at progression, exhibited a significant correlation with progression-free and overall survival, similar to tumor response and progression by Gynecologic Cancer Inter Group criteria. The tumor response at 8 weeks higher than 1.77 appears to be a good surrogate of clinical response, whereas the definition of progression when CA125 increases above a value double than the nadir suggests a similar performance of growth rate at progression versus Gynecologic Cancer Inter Group criteria and warrants further investigation.
引用
收藏
页码：1203 / 1209
页数：7
相关论文
共 50 条
  • [31] MEASUREMENT OF THE OVARIAN CANCER-ASSOCIATED ANTIGEN CA-125 IN MONITORING TUMOR BURDEN AND RESPONSE TO CHEMOTHERAPY
    QUARANTA, M
    COVIELLO, M
    DONADEO, A
    RELLA, C
    LORUSSO, V
    MICELLI, G
    LUCARELLI, C
    TUMORI JOURNAL, 1991, 77 (02): : 167 - 169
  • [32] THE DIAGNOSTIC VALIDITY OF THE TUMOR-MARKER CA-125 IN OVARIAN-CANCER PATIENTS
    SEVELDA, P
    SALZER, H
    DITTRICH, C
    PATEISKY, N
    SPONA, J
    TUMORDIAGNOSTIK & THERAPIE, 1987, 8 (03) : 115 - 120
  • [33] FACTORS PREDICTING OUTCOME FOR ADVANCED GASTROESOPHAGEAL CANCER IN ELDERLY PATIENTS RECEIVING CHEMOTHERAPY: A RETROSPECTIVE ANALYSIS
    Lord, S. R.
    Hall, P. S.
    Seymour, M.
    Mcshane, P.
    Anthony, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 210 - 210
  • [34] The predictive value of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients
    Arie, Van Dalen
    Favier, J.
    Hallesleben, E.
    Burges, A.
    Stieber, P.
    de Bruijn, H. W. A.
    Fink, D.
    Giai, M.
    McGing, P.
    Harlozinska, A.
    Ch, Kainz
    Markowska, J.
    Molina, R.
    Sturgeon, C.
    Bowman, A.
    Einarsson, R.
    Goike, H.
    TUMOR BIOLOGY, 2006, 27 : 8 - 8
  • [35] Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients
    van Dalen, A
    Favier, J
    Burges, A
    Hasholzner, U
    de Bruijn, HWA
    Dobler-Girdziunaite, D
    Dombi, VH
    Fink, D
    Giai, M
    McGing, P
    Harlozinska, A
    Kainz, C
    Markowska, J
    Molina, R
    Sturgeon, C
    Bowman, A
    Einarsson, R
    GYNECOLOGIC ONCOLOGY, 2000, 79 (03) : 444 - 450
  • [36] Prognostic value of serial CA125 measurements during chemotherapy for patients with advanced ovarian cancer
    Koper, NP
    Massuger, LFAG
    Thomas, CMG
    Kiemeney, LALM
    Schijf, CPT
    Beex, LVAM
    Verbeek, ALM
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1997, 7 (02) : 127 - 133
  • [37] Interpretation of the CA125 kinetics during first line chemotherapy of the ovarian cancer: methodological aspects and characteristic profiles
    Riedinger, JM
    Eche, N
    Basuyau, JP
    Daver, A
    Touzery, C
    Mayer, F
    Coudert, B
    Fargeot, P
    Chauffert, B
    de Gislain, C
    Zanetta, S
    ANNALES DE BIOLOGIE CLINIQUE, 2002, 60 (02) : 183 - 191
  • [38] MUCIN-LIKE CARCINOMA-ASSOCIATED ANTIGEN AND CA-125 IN EVALUATION OF CHEMOTHERAPY RESULTS IN OVARIAN-CANCER PATIENTS
    MERIMSKY, O
    HAREUVENI, M
    INBAR, M
    LIMOR, R
    WITENBERG, B
    CHAITCHIK, S
    DIAGNOSTIC ONCOLOGY, 1993, 3 (03): : 117 - 120
  • [39] The added value of CA125 normalization before interval debulking surgery to the chemotherapy response score for the prognostication of ovarian cancer patients receiving neoadjuvant chemotherapy for advanced disease
    Liang, Wei-feng
    Wang, Li-juan
    Li, Hui
    Liu, Chang-hao
    Wu, Miao-fang
    Li, Jing
    JOURNAL OF CANCER, 2021, 12 (03): : 946 - 953
  • [40] The role of PET/CT in the detection of residual/ recurrent tumor in patients with ovarian cancer whose Ca-125 value is within normal limits
    Cekin, G.
    bezircioglu, I.
    Yigit, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S724 - S724
12345